BW-501C67

Overview of the chemical compound BW-501C67

{{Drugbox | verifiedfields = changed | verifiedrevid = 477318123 | IUPAC_name = (2S)-2-[[4-(4-chlorophenyl)-2-thiazolyl]amino]-3-methylbutanoic acid | image = BW-501C67.svg | image_size = 200px | image_alt = Chemical structure of BW-501C67 }}

BW-501C67 is a chemical compound that has been studied for its potential pharmacological properties. It is primarily known for its role as a thromboxane receptor antagonist, which suggests its potential use in modulating platelet aggregation and vascular tone.

Chemical Structure

Chemical structure of BW-501C67

BW-501C67 is characterized by its unique chemical structure, which includes a thiazole ring and a chlorophenyl group. The IUPAC name for BW-501C67 is (2S)-2-[[4-(4-chlorophenyl)-2-thiazolyl]amino]-3-methylbutanoic acid. This structure is significant because it contributes to the compound's ability to interact with specific biological targets, such as the thromboxane receptor.

Pharmacological Properties

BW-501C67 functions as a selective antagonist of the thromboxane receptor. Thromboxane is a biochemical mediator that plays a crucial role in hemostasis and thrombosis. By inhibiting the thromboxane receptor, BW-501C67 can potentially reduce platelet aggregation and prevent the formation of blood clots. This makes it a compound of interest in the development of antithrombotic therapies.

Potential Applications

The primary application of BW-501C67 is in the field of cardiovascular medicine. Its ability to inhibit thromboxane-mediated pathways suggests that it could be used to treat or prevent conditions such as myocardial infarction, stroke, and other thrombotic disorders. Additionally, its effects on vascular tone may have implications for the treatment of hypertension and other cardiovascular diseases.

Research and Development

Research on BW-501C67 has primarily focused on its pharmacodynamics and pharmacokinetics. Studies have been conducted to understand its absorption, distribution, metabolism, and excretion (ADME) properties. These studies are crucial for determining the compound's safety and efficacy in potential therapeutic applications.

Related Pages

• Thromboxane receptor
• Platelet aggregation
• Antithrombotic therapy
• Cardiovascular disease